Genmab — November 2018
-
Tusinde tak Henrik...Tjekker lige op.
-
-
Samme med kursen d.d...;-)
-
Dejligt med den kursudvikling vi har haft i dag
Godt med noget positivt, sådan en mandag, når man lige har tabt en stor ordre på arbejdet 
-
Det fremgår af deres pressemeddelelse de vigtigste aspekter af fase III MAIA studie vil være med. Derudover vil der blive fremlagt
prækliniske data fra Genmabs DuoBody-CD3xCD20 og DuoHexaBody-CD37 programmer præsenteret ved ASH, samt virksomhedens fremskridt og hovedmål for 2019.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind